Affinage

FGF1

Fibroblast growth factor 1 · UniProt P05230

Length
155 aa
Mass
17.5 kDa
Annotated
2026-06-09
100 papers in source corpus 33 papers cited in narrative 33 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FGF1 is a heparin-binding growth factor that operates through two distinct arms: canonical signaling via cell-surface FGF receptors and a receptor-independent intracrine/nuclear pathway, and it has emerged as a potent regulator of systemic metabolism (PMID:28813681, PMID:34986332). At the receptor, FGF1 binding induces FGFR and ligand homodimerization in a heparin-/heparan sulfate-dependent manner (PMID:7686384), and an engineered variant with diminished heparan-sulfate-assisted FGFR dimerization (FGF1ΔHBS) retains full metabolic activity while losing mitogenic potency, establishing that stable receptor dimerization drives proliferation whereas suboptimal dimerization suffices for metabolic responses (PMID:28813681). Metabolically, peripheral FGF1 acutely suppresses adipose lipolysis and hepatic glucose production by activating phosphodiesterase 4D to inhibit the cAMP-PKA axis—mechanistically distinct from insulin's action via PDE3B (PMID:34986332)—and promotes adipocyte glucose uptake through MEK1/2-Akt crosstalk acting on GLUT4 and transcriptional induction of GLUT1 (PMID:36161959). In a parallel intracrine route, exogenous FGF1 is endocytosed and translocated to the cytosol in a PI3K-dependent manner (PMID:10766827), imported into the nucleus via the ER-anchored protein LRRC59 together with importin-α1/β1 and Ran (PMID:22321063), where it binds nucleolin to enable PKCδ-mediated phosphorylation at S130 that triggers nuclear export (PMID:24595027); nuclear FGF1 interacts with p53 and suppresses p53-dependent apoptosis independently of FGFR kinase activity (PMID:19765618, PMID:30099027). FGF1 is secreted by a non-classical, signal-peptide-independent route that requires Cu2+-dependent assembly with S100A13, sphingosine kinase 1, and AHNAK2 (PMID:14625381, PMID:17643421, PMID:25560297), a pathway transcriptionally restrained by Notch/CBF1 signaling (PMID:21302306). Across tissues these activities underlie roles in β-cell compensatory differentiation (PMID:26420862), cardiomyocyte protection and proliferation (PMID:12176126), adipogenesis downstream of mechanical Piezo1 activation (PMID:32385276), and reversal of hepatic steatosis (PMID:36934380).

Mechanistic history

Synthesis pass · year-by-year structured walk · 29 steps
  1. 1991 Medium

    Defined which FGFR regions are dispensable for FGF1 high-affinity binding and activation, refining the receptor-ligand engagement model.

    Evidence truncated FGFR2 (bek) variant expression and binding assays in NIH3T3 cells

    PMID:1722570

    Open questions at the time
    • Does not resolve the structural basis of dimerization
    • Single receptor isoform tested
  2. 1993 Medium

    Established that FGF1 receptor activation proceeds through heparin-modulated FGFR and ligand dimerization, defining the assembly logic of the signaling complex.

    Evidence crosslinking of 125I-aFGF, heparin competition, and a reduced-heparin-affinity mutant

    PMID:7686384

    Open questions at the time
    • Complex stoichiometry inferred rather than structurally resolved
    • Role of specific heparan sulfate proteoglycan not defined
  3. 1996 Medium

    Showed FGF1 neurotrophic/survival activity can be uncoupled from MAP kinase activation, hinting at a receptor-independent intracellular mode.

    Evidence PC12 differentiation assays with FGF1 transfection and MAP kinase activation readouts

    PMID:8576258

    Open questions at the time
    • Intracellular site of action not localized
    • Effector of the MAPK-independent activity unknown at this stage
  4. 2000 High

    Identified PI3K as a requirement for translocation of exogenous FGF1 from the cell surface to the cytosol and nucleus, opening the intracrine trafficking pathway.

    Evidence PI3K chemical inhibition, dominant-negative PI3K, cell fractionation and translocation reporters

    PMID:10766827

    Open questions at the time
    • Identity of PI3K-dependent vesicular machinery undefined
    • Step at which FGF1 crosses the membrane unresolved
  5. 2003 Medium

    Characterized FGF1 non-classical export as a Cu2+-dependent multiprotein process involving S100A13, addressing how a signal-peptide-less protein is released.

    Evidence biochemical export complex characterization and copper chelation inhibition

    PMID:14625381

    Open questions at the time
    • Molten-globule translocation mechanism not directly demonstrated
    • In vivo relevance of copper dependence unclear
  6. 2005 Medium

    Demonstrated that intracellular FGF1 suppresses p53-dependent apoptosis by raising MDM2 and blocking Bax transactivation, establishing an intracrine anti-apoptotic function.

    Evidence intracellular vs. extracellular FGF1 constructs in rat embryonic fibroblasts with apoptosis and target gene readouts

    PMID:16091747

    Open questions at the time
    • Direct vs. indirect FGF1-p53 interaction not shown here
    • Mechanism of MDM2 induction undefined
  7. 2007 Medium

    Placed sphingosine kinase 1 in the copper-dependent FGF1 export complex, expanding the non-classical secretion machinery.

    Evidence cell-free reconstitution, SphK1 knockout/overexpression, copper-chelation rescue

    PMID:17643421

    Open questions at the time
    • Enzymatic vs. structural role of SphK1 not separated
    • Single lab
  8. 2009 Medium

    Linked the FGF1 NLS to both neurotrophic and anti-apoptotic activity and showed wild-type but not ΔNLS FGF1 co-immunoprecipitates with p53.

    Evidence NLS-deletion mutants, fractionation/imaging, FGF1-p53 co-IP, survival assays in PC12 cells

    PMID:19765618

    Open questions at the time
    • Direct binding not confirmed (co-IP only)
    • Whether nuclear entry alone or downstream events drive protection unresolved
  9. 2012 High

    Defined the nuclear import machinery for cytosolic FGF1 as LRRC59/importin-α1/β1/Ran, distinguishing it from FGF2 import.

    Evidence siRNA knockdown of LRRC59 and importins with fractionation and pathway comparison

    PMID:22321063

    Open questions at the time
    • How ER-anchored LRRC59 hands off FGF1 to importins mechanistically unclear
    • Cytosol-to-nucleus shuttling kinetics undefined
  10. 2012 Medium

    Identified RFX1-3 transcription factors binding an 18-bp cis-element of the FGF1 1B promoter as direct regulators of FGF1 expression in neural cells.

    Evidence promoter-reporter, ChIP/EMSA, RFX2 knockdown/overexpression with neurosphere assays

    PMID:22415835

    Open questions at the time
    • Tissue-specific signals controlling RFX complex assembly unknown
    • Other FGF1 promoters not addressed
  11. 2013 Medium

    Showed the FGF1 1B promoter is epigenetically activated via HDAC and GSK-3 inhibition through RFX-bound chromatin, connecting chromatin state to FGF1 induction.

    Evidence promoter reporter, HDAC/GSK-3 inhibitors, GSK-3 siRNA, histone acetylation ChIP

    PMID:23647222

    Open questions at the time
    • Physiological stimulus engaging this axis unknown
    • Direct HDAC isoform not identified
  12. 2014 High

    Established nucleolin as a direct FGF1 partner required for PKCδ phosphorylation of FGF1 and subsequent nuclear export, defining the intranuclear processing step.

    Evidence SPR, affinity pulldown, nucleolin siRNA, FGF1 binding and phosphomimetic mutants, fractionation

    PMID:24595027

    Open questions at the time
    • How nucleolin positions FGF1 for PKCδ not structurally resolved
    • PKCδ recruitment mechanism undefined
  13. 2014 Medium

    Identified an FGFR1-Fn14 receptor interaction enabling synergistic FGF1/TWEAK-driven cardiomyocyte cell cycle reentry via PI3K/Akt.

    Evidence co-IP, proximity ligation, Fn14 and FGFR-1 inhibition, cell cycle assays in cardiomyocytes

    PMID:24571920

    Open questions at the time
    • Whether interaction is direct or scaffold-mediated unknown
    • In vivo relevance not tested
  14. 2015 Medium

    Added AHNAK2 as a stress-induced, heat-shock-dependent component specifically required for non-classical FGF1 (not FGF2) export.

    Evidence co-IP/MS identification, AHNAK2 siRNA, fractionation and export assays

    PMID:25560297

    Open questions at the time
    • Molecular role of AHNAK2 in translocation unknown
    • Interplay with S100A13/SphK1 complex undefined
  15. 2015 High

    Demonstrated in zebrafish that Fgf1 is necessary and sufficient for overnutrition-induced compensatory β-cell differentiation, establishing a physiological metabolic role for secreted FGF1.

    Evidence fgf1 loss-of-function and β-cell rescue genetics, constitutive secretion construct, ER stress manipulation

    PMID:26420862

    Open questions at the time
    • Receptor and downstream effectors in β-cells not defined here
    • Mammalian conservation inferred, not directly shown
  16. 2016 Medium

    Showed cell-surface importin α1 (KPNA2) binds FGF1 and enhances ERK1/2 activation and cancer cell proliferation, expanding importin function beyond nuclear import.

    Evidence surface importin α1 detection, FGF1 co-IP, antibody blockade, proliferation assays

    PMID:26887791

    Open questions at the time
    • Mechanism by which surface importin potentiates ERK unclear
    • Relationship to FGFR signaling complex undefined
  17. 2016 Medium

    Linked FGF1/FGFR signaling to Aurora A activation controlling neurosphere formation and differentiation state in glioblastoma.

    Evidence FGF1 treatment, FGFR and AurA pharmacological inhibition, neurosphere assays in GBM cells

    PMID:27138904

    Open questions at the time
    • Direct vs. indirect AurA activation undefined
    • Pharmacological inhibitors only
  18. 2016 Medium

    Mapped FGF1 K132 and S130 phosphorylation as switches controlling intracrine anti-apoptotic versus neurotrophic activities.

    Evidence K132E/S130A/S130D point mutants in PC12 cells with differentiation and apoptosis assays

    PMID:26844696

    Open questions at the time
    • Structural consequence of phosphorylation not determined
    • Kinase responsible inferred from prior work
  19. 2017 Medium

    Confirmed the S130-phosphorylation-dependent, cell-type-specific intracrine anti-apoptotic pathway in neuroblastoma cells.

    Evidence recombinant and overexpressed FGF1 mutants in SH-SY5Y vs. N2a cells, etoposide apoptosis assays

    PMID:29048426

    Open questions at the time
    • Basis of cell-type specificity unknown
    • Single lab
  20. 2017 High

    Separated mitogenic from metabolic FGF1 activity using FGF1ΔHBS, showing stable FGFR dimerization is required for proliferation but not for glucose homeostasis—a foundation for safer metabolic therapeutics.

    Evidence heparin-binding-site mutagenesis, in vitro proliferation and in vivo metabolic and dimerization assays

    PMID:28813681

    Open questions at the time
    • Receptor signaling differences driving the divergence not fully defined
    • Long-term in vivo consequences not addressed
  21. 2018 High

    Decisively dissociated FGF1 anti-apoptotic activity from FGFR kinase signaling and tied it to nucleolin-dependent nuclear phosphorylation.

    Evidence FGFR kinase inhibitors, kinase-dead FGFR1, translocation inhibitors, nucleolin-binding mutants, apoptosis assays across cell lines

    PMID:30099027

    Open questions at the time
    • Direct nuclear targets beyond p53 not enumerated
    • Quantitative contribution of intracrine vs. receptor pathways in vivo unknown
  22. 2018 Medium

    Identified CSPG4 (NG2) and CD44 as cell-surface FGF1-binding proteoglycans acting as reservoir/storage molecules beyond FGFRs.

    Evidence APEX2-FGF1 proximity labeling/proteomics, colocalization, heparin-binding mutant analysis

    PMID:29812912

    Open questions at the time
    • Functional consequence of reservoir binding on signaling not quantified
    • Whether these modulate receptor presentation untested
  23. 2019 Medium

    Defined Erk1/2 and p38 as redundant negative-feedback kinases phosphorylating FRS2 to downregulate FGF1-induced FGFR1 signaling.

    Evidence Erk/p38 inhibition and anisomycin activation in NIH3T3 and U2OS-FGFR1 cells with phosphorylation Westerns

    PMID:31013829

    Open questions at the time
    • FRS2 phosphosites not mapped
    • In vivo significance of feedback redundancy untested
  24. 2020 High

    Connected mechanical Piezo1 activation to FGF1 release driving FGFR1-dependent adipogenesis, establishing a mechanotransduction-to-FGF1 axis.

    Evidence adipocyte-specific Piezo1 knockout mice on high-fat diet, FGF1 release and FGFR1 activation assays

    PMID:32385276

    Open questions at the time
    • Secretion route engaged by Piezo1 not specified
    • Link to known non-classical export machinery undefined
  25. 2021 High

    Identified AMPK-Nur77 as the required downstream axis for FGF1ΔHBS protection against diabetic cardiomyopathy via improved mitochondrial function.

    Evidence db/db and AMPK-null mice, FGF1ΔHBS administration, RNA-seq, mitochondrial assays

    PMID:33762571

    Open questions at the time
    • How FGFR signaling activates AMPK not resolved
    • Receptor isoform mediating the response not identified
  26. 2022 High

    Established that peripheral FGF1 suppresses lipolysis and hepatic glucose production by activating PDE4D to inhibit cAMP-PKA, mechanistically distinct from insulin.

    Evidence in vivo FGF1 administration, phosphodiesterase activity and phosphoproteomics (PDE4D Ser44), pharmacological PDE4 inhibition

    PMID:34986332

    Open questions at the time
    • How FGFR signaling converges on PDE4D Ser44 phosphorylation unresolved
    • Tissue-specific receptor requirement undefined
  27. 2022 High

    Defined the dual MEK1/2-Akt (acute GLUT4) and MEK1/2-transcriptional (GLUT1) mechanisms by which FGF1 drives adipocyte glucose uptake.

    Evidence 3T3-L1 and adipose explants, FGF1 knockout mice, MEK1/2 and Akt inhibitors, GLUT trafficking assays

    PMID:36161959

    Open questions at the time
    • Crosstalk node linking MEK1/2 to Akt not pinpointed
    • Receptor isoform driving uptake undefined
  28. 2022 Medium

    Linked FGF1/FGFR signaling to estradiol-independent estrogen receptor phosphorylation and glycolytic reprogramming in endocrine-resistant breast cancer.

    Evidence proteomics, phosphoproteomics, metabolic assays in breast cancer cells, validation in obese mouse tumors

    PMID:37608351

    Open questions at the time
    • Direct kinase linking FGFR to ER phosphorylation unidentified
    • Causality of metabolic shift vs. correlation incompletely separated
  29. 2023 Medium

    Showed FGF1 reverses hepatic steatosis via an epigenetic mechanism: reduced DNMT3A recruitment derepresses IGFBP2, which mediates the metabolic benefit.

    Evidence FGF1 in HFD mice, DNMT3A ChIP, bisulfite sequencing, AAV-IGFBP2 knockdown epistasis

    PMID:36934380

    Open questions at the time
    • How FGFR signaling controls DNMT3A locus occupancy unknown
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the receptor-dependent metabolic signaling arm (PDE4D, MEK1/2-Akt, AMPK, epigenetic IGFBP2) is mechanistically coupled to specific FGFR isoforms and co-receptors in each target tissue, and how this integrates with the intracrine nuclear pathway in vivo, remains unresolved.
  • No unified map linking receptor isoform usage to tissue-specific metabolic effectors
  • Relative in vivo contribution of intracrine vs. receptor pathways unquantified
  • Structural basis of the suboptimal-dimerization metabolic signal undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 3 GO:0008289 lipid binding 2 GO:0060089 molecular transducer activity 2
Localization
GO:0005576 extracellular region 3 GO:0005634 nucleus 3 GO:0005886 plasma membrane 3 GO:0005829 cytosol 2 GO:0005730 nucleolus 1
Pathway
R-HSA-1430728 Metabolism 3 R-HSA-162582 Signal Transduction 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-1266738 Developmental Biology 2 R-HSA-9609507 Protein localization 2
Partners
AHNAK2FGFR1KPNA2LRRC59NUCLEOLINP53S100A13SPHK1
Complex memberships
Cu2+-dependent FGF1 non-classical export complex (S100A13/SphK1/AHNAK2)FGF1-FGFR-heparan sulfate signaling complex

Evidence

Reading pass · 33 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 FGF1 non-classical export (lacking an N-terminal signal sequence) depends on Cu2+-dependent formation of multiprotein complexes containing the S100A13 protein, and the protein may translocate across the membrane as a 'molten globule'. Biochemical characterization of export complex components; copper chelation inhibition experiments Journal of cell science Medium 14625381
2007 Sphingosine kinase 1 (SphK1) is a component of the copper-dependent FGF1 non-classical export pathway: SphK1 forms a complex with FGF1 in a cell-free system in a copper-dependent manner, SphK1-null cells fail to release FGF1 under stress, and SphK1 overexpression rescues FGF1 release from inhibition by a copper chelator. Cell-free complex reconstitution, SphK1 knockout/overexpression, copper chelation rescue experiments Experimental cell research Medium 17643421
2000 Translocation of exogenous aFGF from the cell surface to the cytosol and nucleus requires phosphatidylinositol 3-kinase (PI3K) activity; inhibition of PI3K by chemical inhibitors or dominant-negative PI3K blocks cytosolic and nuclear translocation of aFGF, and PI3K-inhibited cells retain a diphtheria toxin–aFGF fusion protein in the cytosol rather than allowing nuclear entry. PI3K chemical inhibition, dominant-negative PI3K expression, cell fractionation, farnesylation and PKC phosphorylation reporters for translocation The Journal of biological chemistry High 10766827
2012 Nuclear import of exogenous FGF1 (after cytosolic translocation) requires the ER-anchored protein LRRC59, Ran GTPase, importin-α1 (Kpnα1), and importin-β1 (Kpnβ1), as well as a nuclear localization sequence (NLS) in FGF1. LRRC59 depletion by siRNA does not block cytosolic translocation but blocks nuclear import of FGF1; nuclear import of FGF2 is independent of LRRC59 but dependent on the same importins. siRNA knockdown of LRRC59, Kpnα1, Kpnβ1; cell fractionation; localization imaging; comparison with FGF2 import pathway Traffic (Copenhagen, Denmark) High 22321063
2014 Nucleolin binds directly to FGF1 (interaction confirmed by surface plasmon resonance and pulldown) at residues within the heparin-binding site; nucleolin is required for intranuclear phosphorylation of FGF1 by PKCδ, and this phosphorylation event is required for nuclear export of FGF1. In nucleolin-depleted cells, FGF1 enters the nucleus but is neither phosphorylated by PKCδ nor exported. Affinity pulldown, surface plasmon resonance, nucleolin siRNA depletion, FGF1 phosphomimetic and binding mutants, nuclear fractionation PloS one High 24595027
2009 FGF1 nuclear translocation (via its NLS) is required for both its neurotrophic/differentiation activity and its protection against p53-dependent apoptosis in PC12 cells; deletion of the NLS (FGF1ΔNLS) abolishes nuclear localization and both activities. Wild-type FGF1 interacts with p53 (co-immunoprecipitation), whereas ΔNLS-FGF1 does not. Transfection of FGF1 NLS-deletion mutants, nuclear fractionation/imaging, co-immunoprecipitation of FGF1 with p53, differentiation and survival assays Biochimica et biophysica acta Medium 19765618
2005 Intracellular (intracrine) FGF1 inhibits p53-dependent apoptosis and cell growth arrest via an intracrine pathway; it increases MDM2 expression (mRNA and protein), accelerating p53 degradation, and prevents Bax transactivation by p53. p53 activation represses FGF1 gene expression. Extracellular FGF1 has no effect on p53-dependent pathways. Transfection of intracellular vs. extracellular FGF1 constructs in rat embryonic fibroblasts; apoptosis/cell cycle assays; Western blot and RT-PCR for MDM2 and p53 targets Oncogene Medium 16091747
2016 FGF1 C-terminal residue K132 and phosphorylation of S130 regulate intracrine FGF1 anti-apoptotic activity in PC12 cells: K132E mutation abolishes both neurotrophic and anti-apoptotic activities; FGF1(S130A) (non-phosphorylatable) protects against p53-dependent apoptosis, whereas FGF1(S130D) (phosphomimetic) does not, indicating that phosphorylation inhibits anti-apoptotic activity but does not affect neurotrophic/differentiation activity. Transfection of FGF1 point mutants (K132E, S130A, S130D) in PC12 cells; differentiation and apoptosis assays Cell death & disease Medium 26844696
2017 FGF1 protects neuroblastoma SH-SY5Y cells from p53-dependent apoptosis through an intracrine pathway regulated by FGF1 phosphorylation at S130 and the C-terminal domain (K132). FGF1 phosphorylation status determines intracrine (but not extracellular pathway) anti-apoptotic activity; this effect is cell-type specific (absent in N2a cells). Recombinant FGF1 addition and FGF1 overexpression with point mutants (K132E, S130A, S130D) in SH-SY5Y and N2a cells; apoptosis assays; etoposide treatment Cell death & disease Medium 29048426
2018 Intracellular FGF1 (translocated from endosomes into the cytosol/nucleus) protects cells against apoptosis independently of FGFR activation and downstream signaling; this anti-apoptotic effect is abolished by inhibitors of endosome-to-cytosol translocation but not by potent FGFR kinase inhibitors. FGF1 mutations preventing binding to nucleolin (thereby preventing nuclear phosphorylation) reduce the anti-apoptotic activity, linking nuclear phosphorylation to anti-apoptotic function. FGFR kinase inhibitors, FGFR1 kinase-dead mutant, translocation inhibitors, nucleolin-binding FGF1 mutants; serum starvation and staurosporine apoptosis assays Journal of molecular biology High 30099027
2015 AHNAK2 associates with FGF1 in a heat-shock-dependent manner (identified by co-immunoprecipitation/mass spectrometry); AHNAK2 depletion drastically decreases stress-induced FGF1 export but does not affect spontaneous FGF2 export or Notch-inhibition-induced FGF1 release, placing AHNAK2 specifically in the stress-induced non-classical FGF1 export pathway. Immunoprecipitation/mass spectrometry, AHNAK2 siRNA depletion, subcellular fractionation, FGF1 export assays under heat shock Journal of cellular biochemistry Medium 25560297
2011 Non-classical FGF1 release and FGF1-dependent cell transformation are regulated by Notch signaling through transcription factor CBF1: dominant-negative CBF1 induces FGF1 and SphK1 transcription and stimulates stress-independent FGF1 release; the transformed phenotype of dnCBF1 cells is blocked by dominant-negative FGFR1 or dominant-negative S100A13; FGF1 export and cell proliferation induced by dnCBF1 depend on SphK1. Dominant-negative CBF1 and MAML transfection, colony formation assay, tumor xenograft, FGF1 export assay, FGF1-null cells Journal of cellular physiology Medium 21302306
1996 FGF1 neurotrophic activity (neuronal differentiation and serum-free survival) in PC12 cells requires endogenous FGF1 expression and is independent of the MAP kinase cascade; MAP kinase (ERK1) is activated equally by FGF1, FGF1+heparin, and a mutated FGF1, but only FGF1+heparin promotes differentiation. Constitutive or inducible overexpression of FGF1 directly promotes differentiation and survival proportional to the level of FGF1 expressed. MAP kinase activation assays, PC12 differentiation assays, FGF1 transfection with constitutive and inducible expression vectors, serum-free survival The Journal of biological chemistry Medium 8576258
2017 An FGF1 partial agonist carrying triple mutations (FGF1ΔHBS) that diminish heparan sulfate (HS)-assisted FGFR dimerization has severely reduced mitogenic/proliferative activity while retaining full metabolic activity; this establishes that stable FGFR dimerization is required for mitogenesis but suboptimal FGFR activation by a weak FGF1-FGFR dimer is sufficient for metabolic responses (glucose homeostasis). Site-directed mutagenesis of heparin-binding site, in vitro proliferation assays, in vivo metabolic assays in mice, receptor dimerization assays Cell reports High 28813681
2022 FGF1 acutely suppresses adipose lipolysis and hepatic glucose production by inhibiting the cAMP-PKA axis through activation of phosphodiesterase 4D (PDE4D), which is mechanistically distinct from insulin's inhibitory action via PDE3B. FGF1-induced Ser44 phosphorylation of PDE4D is a regulatory site modulated by the feed-fast cycle. In vivo FGF1 administration with lipolysis and hepatic glucose production assays; phosphodiesterase activity assays; phosphoproteomics identifying PDE4D Ser44; pharmacological PDE4 inhibition Cell metabolism High 34986332
2022 FGF1 increases glucose uptake in adipocytes via two mechanisms: acutely, through MEK1/2 and Akt crosstalk activating the insulin-sensitive glucose transporter GLUT4; and with prolonged exposure, through MEK1/2-dependent transcriptional upregulation of the basal glucose transporter GLUT1. FGF1 knockout mice have reduced adipose glucose uptake. FGF1 treatment of 3T3-L1 adipocytes and ex vivo adipose explants; FGF1 knockout mice; MEK1/2 and Akt inhibitors; GLUT1/GLUT4 expression and trafficking assays Proceedings of the National Academy of Sciences of the United States of America High 36161959
2020 In adipocytes, mechanical activation of Piezo1 causes release of FGF1, which then induces preadipocyte differentiation (adipogenesis) through activation of FGF receptor 1 (FGFR1). Mice lacking Piezo1 in mature adipocytes show defective preadipocyte differentiation under high-fat diet. Adipocyte-specific Piezo1 knockout mice on high-fat diet; FGF1 release assays; FGFR1 activation assays; preadipocyte differentiation assays Nature communications High 32385276
2015 In zebrafish, Fgf1 signaling is necessary and sufficient for overnutrition-induced compensatory β-cell differentiation: fgf1 inactivation abolishes compensatory β-cell differentiation; expression of human FGF1 solely in β-cells rescues the response in fgf1-/- animals; constitutive FGF1 secretion with an exogenous signal peptide increases β-cell number without overnutrition. FGF1 is secreted from β-cells during prolonged activation, with ER stress acting upstream of FGF1 release. Zebrafish fgf1 loss-of-function and rescue genetics, constitutive FGF1 secretion construct, small-molecule screen, β-cell differentiation assay, ER stress manipulation Diabetes High 26420862
2014 FGFR-1 interacts with the TNF receptor superfamily member Fn14 (co-immunoprecipitation and proximity ligation assay in cardiomyocytes); FGF1-induced cardiomyocyte cell cycle reentry is blocked by Fn14 inhibition, and TWEAK-induced cell cycle activation is blocked by FGFR-1 inhibition; costimulation with FGF1 and TWEAK synergistically induces cell cycle reentry via PI3K/Akt signaling. Co-immunoprecipitation, proximity ligation assay, Fn14 siRNA inhibition, FGFR-1 blockade, PI3K/Akt pathway analysis, cardiomyocyte cell cycle assays FASEB journal Medium 24571920
2002 Cardiac-specific overexpression of FGF1 in transgenic mice delays infarct development and provides cardiomyocyte-level protection independently of angiogenesis, at least partially through constitutively elevated ERK-1/2 activity; ERK-1/2 inhibitor (UO126) reduces the cardioprotective effect. Transgenic mouse coronary occlusion model, infarct size measurement, ERK-1/2 Western blot, ERK inhibitor treatment, isolated cardiomyocyte ischemia simulation Cardiovascular research Medium 12176126
2016 Cell-surface-localized importin α1 (KPNA2) binds directly to FGF1 (a cNLS-containing growth factor) and enhances ERK1/2 activation downstream of FGF1 signaling; anti-importin α1 antibody suppresses FGF1-importin α1 complex formation and ERK1/2 activation, reducing cancer cell proliferation. Cell surface importin α1 detection, co-immunoprecipitation of importin α1 with FGF1, ERK1/2 phosphorylation assays, anti-importin α1 antibody inhibition, proliferation assays Scientific reports Medium 26887791
2018 FGF1 binds cell-surface proteoglycans CSPG4 (NG2) and CD44 in addition to FGFRs; FGF1 binds CD44 through its heparin-binding moiety; both CSPG4 and CD44 colocalize with FGF1 at the cell surface and likely act as storage/reservoir molecules for FGF1. APEX2-FGF1 proximity labeling on living cells followed by proteomics; signaling validation of fusion protein; colocalization imaging; heparin-binding domain mutant analysis Biochemistry Medium 29812912
1991 Both high-affinity aFGF (and bFGF) binding and receptor activation by aFGF/bFGF do not require the N-terminal first Ig-like domain and acidic motif of the FGFR (bek/FGFR2); a truncated bek variant lacking these regions is sufficient for high-affinity binding and cell activation. cDNA cloning and overexpression of truncated FGFR variants in NIH3T3 cells; FGF binding assay Oncogene Medium 1722570
1995 aFGF and bFGF induce membrane ruffling in breast cancer cells (but not normal breast epithelial cells) through FGFR-4; dominant-negative FGFR-3 or dominant-negative p21rac inhibits membrane ruffling, establishing that receptor dimerization/phosphorylation and Rac activation are prerequisites; transient transfection showed FGFR-1, -2, -3 cannot mediate ruffling while FGFR-4 can. Dominant-negative FGFR3 and Rac transfection, transient transfection of individual FGFRs in COS-7 cells, morphological membrane ruffling assay The Biochemical journal Medium 7534069
2001 FGF-1 (and FGF-2) upregulate E-cadherin, β-catenin, and α-catenin protein levels in pancreatic cancer cells and facilitate the association of E-cadherin and α-catenin with the cytoskeleton (shown by increased detergent-insoluble fraction). FGFs also elevate tyrosine phosphorylation of E-cadherin, α-, β-, and γ-catenins (but not p120ctn), suggesting FGF/FGFR signaling regulates the E-cadherin/catenin complex. FGF-1 treatment of pancreatic cancer cell lines, Western blot for cadherin/catenin levels, Triton X-100 fractionation for cytoskeletal association, tyrosine phosphorylation Western blot International journal of cancer Medium 11745459
2019 Both Erk1/2 and p38 kinase phosphorylate FRS2 (a major FGFR1 signaling mediator) as part of negative-feedback downregulation of FGF1-induced signaling. Simultaneous inhibition of both Erk1/2 and p38 produces significantly prolonged FGFR1 and FRS2 tyrosine phosphorylation compared to Erk inhibition alone, and excessive p38 activation can partially compensate for absent Erk activity. Pharmacological inhibition of Erk1/2 and/or p38 in NIH3T3 and U2OS-FGFR1 cells; anisomycin p38 activation; Western blot for FGFR1 and FRS2 phosphorylation International journal of molecular sciences Medium 31013829
2013 The FGF1 gene 1B promoter is activated by valproic acid (VPA) through inhibition of HDAC (histone deacetylases) and GSK-3 activities; VPA causes increased histone H3 acetylation at an 18-bp cis-element of the FGF-1B promoter and alters RFX1-3 transcriptional complex binding. FGF-1B promoter-GFP reporter, HDAC and GSK-3 inhibitors (sodium butyrate, trichostatin A, lithium), GSK-3 siRNA, ChIP for histone acetylation Journal of neurochemistry Medium 23647222
2012 RFX1, RFX2, and RFX3 transcription factors directly bind an 18-bp cis-element (-484 to -467) in the human FGF1 gene 1B promoter to regulate its activity; RFX2/RFX3 complex is detected only in FGF-1B positive cells; RFX2 knockdown reduces FGF-1B(+) cell proportion and neurosphere formation while RFX2 overexpression has opposite effects. Promoter-reporter assays, ChIP/EMSA for RFX binding, RFX2 siRNA knockdown and overexpression, neurosphere assays Journal of cellular biochemistry Medium 22415835
2023 FGF1 ameliorates hepatic steatosis by inducing IGFBP2 expression through reducing recruitment of DNA methyltransferase 3α (DNMT3A) to the IGFBP2 genomic locus, decreasing IGFBP2 gene methylation and increasing its expression; AAV-mediated IGFBP2 suppression diminishes the therapeutic benefit of FGF1 on hepatic steatosis, demonstrating that this epigenetic IGFBP2 pathway mediates FGF1 metabolic action. Recombinant FGF1 treatment in HFD mice, ChIP for DNMT3A at IGFBP2 locus, bisulfite sequencing for methylation, AAV-IGFBP2 knockdown epistasis, palmitic acid hepatocyte model FASEB journal Medium 36934380
2016 FGF1/FGFR signaling activates Aurora A (AurA) kinase (Thr288 phosphorylation) in glioblastoma cells; FGFR inhibitor (SU5402) down-regulates AurA activity and AurA inhibitors reduce neurosphere formation and induce neuronal differentiation of FGF1B(+) GBM cells. FGF1 treatment and FGFR inhibition in GBM cell lines, AurA phosphorylation Western blot, FACS isolation of F1BGFP+ cells, neurosphere assays, AurA inhibitors Experimental cell research Medium 27138904
2021 FGF1ΔHBS (reduced heparin-binding, low-mitogenicity variant) protects against diabetic cardiomyopathy by activating AMPK, which suppresses Nur77 expression, leading to reduced mitochondrial fragmentation, ROS, and cytochrome c leakage and enhanced mitochondrial respiration; protective effects are absent in AMPK-null mice, establishing AMPK as a required downstream mediator. db/db mouse model, FGF1ΔHBS administration, RNA-seq, AMPK knockout mice, mitochondrial function assays, ROS and apoptosis assays in vitro and in vivo Signal transduction and targeted therapy High 33762571
1993 aFGF binding to cell-surface receptors induces both high-affinity receptor (HAR/FGFR1) dimerization and aFGF homodimerization; the 150 kDa HAR-aFGF complex is proposed to consist of one FGFR1 associated with one heparan sulfate proteoglycan (LAR) via aFGF dimerization. Heparin suppresses formation of the 150 kDa complex and the aFGF dimer on LAR. An aFGF mutant with reduced heparin affinity does not promote dimerization. Only HAR (not LAR) directly mediates aFGF internalization. Cross-linking experiments with 125I-aFGF, receptor binding and internalization assays, heparin competition, aFGF mutant with reduced heparin affinity Growth factors (Chur, Switzerland) Medium 7686384
2022 FGF1 promotes a glycolytic metabolic phenotype in endocrine-resistant breast cancer cells by stimulating estrogen receptor (ER) phosphorylation independently of estradiol; this estrogen-independent ER activation and metabolic reprogramming involves the FGF/FGFR axis. Untargeted proteomics, phospho-proteomics, gene expression profiling, functional metabolic assessments in breast cancer cells; validated in obese mouse tumor samples Breast cancer research Medium 37608351

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2006 FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America 301 17032753
2003 The non-classical export routes: FGF1 and IL-1alpha point the way. Journal of cell science 163 14625381
2020 Adipocyte Piezo1 mediates obesogenic adipogenesis through the FGF1/FGFR1 signaling pathway in mice. Nature communications 126 32385276
2015 Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. Respiratory research 109 26138239
2021 FGF1ΔHBS prevents diabetic cardiomyopathy by maintaining mitochondrial homeostasis and reducing oxidative stress via AMPK/Nur77 suppression. Signal transduction and targeted therapy 100 33762571
2017 TUG1 knockdown ameliorates atherosclerosis via up-regulating the expression of miR-133a target gene FGF1. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 99 29268138
1997 Transfection with aFGF cDNA improves wound healing. The Journal of investigative dermatology 87 9036931
2022 FGF1 alleviates LPS-induced acute lung injury via suppression of inflammation and oxidative stress. Molecular medicine (Cambridge, Mass.) 86 35764933
2022 FGF1 and insulin control lipolysis by convergent pathways. Cell metabolism 85 34986332
2017 FGF1 - a new weapon to control type 2 diabetes mellitus. Nature reviews. Endocrinology 85 28664920
2017 Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. Cell reports 84 28813681
2019 FGF1ΔHBS ameliorates chronic kidney disease via PI3K/AKT mediated suppression of oxidative stress and inflammation. Cell death & disease 82 31189876
2007 VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC musculoskeletal disorders 78 17204151
2002 Peripheral nerve grafts and aFGF restore partial hindlimb function in adult paraplegic rats. Journal of neurotrauma 76 12427329
1994 aFGF, bFGF and flg mRNAs show distinct patterns of induction in the hippocampus following kainate-induced seizures. The European journal of neuroscience 73 7510570
1992 Effects of acidic and basic fibroblast growth factors (aFGF, bFGF) on glial precursor cell proliferation: age dependency and brain region specificity. Developmental biology 70 1379560
1996 The neurotrophic activity of fibroblast growth factor 1 (FGF1) depends on endogenous FGF1 expression and is independent of the mitogen-activated protein kinase cascade pathway. The Journal of biological chemistry 65 8576258
2008 FGF-1: from biology through engineering to potential medical applications. Critical reviews in clinical laboratory sciences 62 18293181
2022 MicroRNA-27b-3p down-regulates FGF1 and aggravates pathological cardiac remodelling. Cardiovascular research 60 34358309
1991 High-affinity binding and activation of a truncated FGF receptor by both aFGF and bFGF. Oncogene 59 1722570
1994 Up-regulation of aFGF expression in quiescent cells is related to cell survival. Journal of cellular physiology 57 7510293
1993 GAP-43, aFGF, CCK and alpha- and beta-CGRP in rat spinal motoneurons subjected to axotomy and/or dorsal root severance. The European journal of neuroscience 56 7506107
2012 Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnα1 and Kpnβ1. Traffic (Copenhagen, Denmark) 54 22321063
2020 aFGF alleviates diabetic endothelial dysfunction by decreasing oxidative stress via Wnt/β-catenin-mediated upregulation of HXK2. Redox biology 53 33360774
2000 TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. International journal of oncology 53 10938383
1999 aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. The Journal of pathology 49 10629559
1995 bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: FGFR-4 involvement. The Biochemical journal 49 7534069
2017 Fibroblast Growth Factor Type 1 (FGF1)-Overexpressed Adipose-Derived Mesenchaymal Stem Cells (AD-MSCFGF1) Induce Neuroprotection and Functional Recovery in a Rat Stroke Model. Stem cell reviews and reports 46 28795363
1999 Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers. British journal of cancer 46 10098767
2009 FGF1 nuclear translocation is required for both its neurotrophic activity and its p53-dependent apoptosis protection. Biochimica et biophysica acta 44 19765618
2002 Angiogenesis-independent cardioprotection in FGF-1 transgenic mice. Cardiovascular research 44 12176126
1988 Development and testing of radio and enzyme immunoassays for acidic fibroblast growth factor (aFGF). Analytical biochemistry 44 3056106
2021 MiR-205-5p suppresses angiogenesis in gastric cancer by downregulating the expression of VEGFA and FGF1. Experimental cell research 43 33957117
2009 Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Molecular therapy : the journal of the American Society of Gene Therapy 43 19240689
2022 Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis. Neoplasia (New York, N.Y.) 41 35378464
2005 FGF-1 and S100A13 possibly contribute to angiogenesis in endometriosis. Journal of reproductive immunology 41 16165218
1996 aFGF, bFGF and NGF differentially regulate neuropeptide expression in dorsal root ganglia after axotomy and induce autotomy. Regulatory peptides 41 8916273
2010 Immunohistochemical study of the growth factors, aFGF, bFGF, PDGF-AB, VEGF-A and its receptor (Flk-1) during arteriogenesis. Molecular and cellular biochemistry 40 20559689
1992 Endogenous aFGF expression and cellular changes after a demyelinating lesion in the spinal cord of adult normal mice: immunohistochemical study. Journal of neuroscience research 39 1280690
1998 Effects of aFGF, bFGF, TGFbeta1 and IGF-I on odontoblast differentiation in vitro. European journal of oral sciences 38 9541212
2024 The Combination of Vascular Endothelial Growth Factor A (VEGF-A) and Fibroblast Growth Factor 1 (FGF1) Modified mRNA Improves Wound Healing in Diabetic Mice: An Ex Vivo and In Vivo Investigation. Cells 37 38474378
2005 FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway. Oncogene 37 16091747
2016 Cell surface localization of importin α1/KPNA2 affects cancer cell proliferation by regulating FGF1 signalling. Scientific reports 36 26887791
2017 FGF1 and IGF1-conditioned 3D culture system promoted the amplification and cancer stemness of lung cancer cells. Biomaterials 35 29017078
2017 lncRNA-Map2k4 sequesters miR-199a to promote FGF1 expression and spinal cord neuron growth. Biochemical and biophysical research communications 34 28655615
2015 FGF1-FGFR1 axis promotes tongue squamous cell carcinoma (TSCC) metastasis through epithelial-mesenchymal transition (EMT). Biochemical and biophysical research communications 34 26362179
1996 Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma research 34 8819125
2000 Requirement of phosphatidylinositol 3-kinase activity for translocation of exogenous aFGF to the cytosol and nucleus. The Journal of biological chemistry 33 10766827
1987 Biomaterial pretreatment with ECGF to augment endothelial cell proliferation. Journal of vascular surgery 33 2950245
2022 Resveratrol and FGF1 Synergistically Ameliorates Doxorubicin-Induced Cardiotoxicity via Activation of SIRT1-NRF2 Pathway. Nutrients 32 36235670
2001 Endothelial cell growth factor (ECGF) enmeshed with fibrin matrix enhances proliferation of EC in vitro. Biomaterials 32 11545311
2000 Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Experimental neurology 32 10683301
2001 FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma. International journal of cancer 31 11745459
2021 A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity. Redox biology 30 34990928
1998 Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers. Cancer letters 30 9751263
2020 Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway. Aging 28 32615540
2016 Computational drill down on FGF1-heparin interactions through methodological evaluation. Glycoconjugate journal 28 27858202
2013 The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities. Journal of neurochemistry 28 23647222
1996 Tissue distribution of human gliostatin/platelet-derived endothelial cell growth factor (PD-ECGF) and its drug-induced expression. Biochimica et biophysica acta 28 8972720
2020 miR-143-3p inhibits proliferation and invasion of hepatocellular carcinoma cells by regulating its target gene FGF1. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 27 32617870
2018 Translocation of Exogenous FGF1 and FGF2 Protects the Cell against Apoptosis Independently of Receptor Activation. Journal of molecular biology 27 30099027
2015 FGF1 Mediates Overnutrition-Induced Compensatory β-Cell Differentiation. Diabetes 27 26420862
2014 Identification of a novel aFGF-binding peptide with anti-tumor effect on breast cancer from phage display library. Biochemical and biophysical research communications 27 24530908
2014 FGF1-mediated cardiomyocyte cell cycle reentry depends on the interaction of FGFR-1 and Fn14. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 27 24571920
2015 AHNAK2 Participates in the Stress-Induced Nonclassical FGF1 Secretion Pathway. Journal of cellular biochemistry 26 25560297
1993 aFGF binding to low and high affinity receptors induces both aFGF and aFGF receptors dimerization. Growth factors (Chur, Switzerland) 26 7686384
2024 Microneedle Patch for Transdermal Sequential Delivery of KGF-2 and aFGF to Enhance Burn Wound Therapy. Small (Weinheim an der Bergstrasse, Germany) 25 38623988
2020 Myocardial protection by nanomaterials formulated with CHIR99021 and FGF1. JCI insight 25 32453715
1998 Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers. Cancer letters 25 9563652
2019 LncRNA TUG1 regulates FGF1 to enhance endothelial differentiation of adipose-derived stem cells by sponging miR-143. Journal of cellular biochemistry 23 31264280
2017 FGF1 protects neuroblastoma SH-SY5Y cells from p53-dependent apoptosis through an intracrine pathway regulated by FGF1 phosphorylation. Cell death & disease 23 29048426
2016 Activation of Aurora A kinase through the FGF1/FGFR signaling axis sustains the stem cell characteristics of glioblastoma cells. Experimental cell research 23 27138904
2007 Sphingosine kinase 1 is a critical component of the copper-dependent FGF1 export pathway. Experimental cell research 23 17643421
2022 Circular RNA circLMF1 regulates PDGF-BB-induced proliferation and migration of human aortic smooth muscle cells by regulating the miR-125a-3p/VEGFA or FGF1 axis. Clinical hemorheology and microcirculation 22 34092624
2016 FGF1 C-terminal domain and phosphorylation regulate intracrine FGF1 signaling for its neurotrophic and anti-apoptotic activities. Cell death & disease 22 26844696
2002 Effects of IL6 and IL1beta on aFGF expression and excitotoxicity in NT2N cells. Journal of neuroimmunology 22 12044971
2022 Autocrine FGF1 signaling promotes glucose uptake in adipocytes. Proceedings of the National Academy of Sciences of the United States of America 21 36161959
2016 Advanced Interfere Treatment of Diabetic Cardiomyopathy Rats by aFGF-Loaded Heparin-Modified Microbubbles and UTMD Technique. Cardiovascular drugs and therapy 21 26947349
1999 Autocrine induction of gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) and GLS-induced expression of matrix metalloproteinases in rheumatoid arthritis synoviocytes. Rheumatology (Oxford, England) 21 10587545
1990 Characterization of the hamster DDT-1 cell aFGF/HGBF-I gene and cDNA and its modulation by steroids. Journal of cellular biochemistry 21 1693366
2023 FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer. Breast cancer research : BCR 20 37608351
2022 Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway. Frontiers in pharmacology 20 36110535
2021 Methacrylated gelatin shape-memorable cryogel subcutaneously delivers EPCs and aFGF for improved pressure ulcer repair in diabetic rat model. International journal of biological macromolecules 20 34973992
2018 Proximity Labeling by a Recombinant APEX2-FGF1 Fusion Protein Reveals Interaction of FGF1 with the Proteoglycans CD44 and CSPG4. Biochemistry 20 29812912
2018 Improving the protective effects of aFGF for peripheral nerve injury repair using sulfated chitooligosaccharides. Asian journal of pharmaceutical sciences 20 32104478
2012 Ciliogenic RFX transcription factors regulate FGF1 gene promoter. Journal of cellular biochemistry 20 22415835
2003 Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy. International journal of radiation oncology, biology, physics 20 12909236
2019 Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling. International journal of molecular sciences 19 31013829
2014 Nucleolin regulates phosphorylation and nuclear export of fibroblast growth factor 1 (FGF1). PloS one 19 24595027
1993 Developmental regulation of acidic fibroblast growth factor (aFGF) expression in bovine retina. The International journal of developmental biology 19 7507349
2019 Identification of a peptide antagonist of the FGF1-FGFR1 signaling axis by phage display selection. FEBS open bio 18 30968602
2008 Evaluation of aFGF/bFGF and FGF signaling pathway in the wall of varicose veins. The Journal of surgical research 18 19394961
2011 Regulation of non-classical FGF1 release and FGF-dependent cell transformation by CBF1-mediated notch signaling. Journal of cellular physiology 16 21302306
1998 Production and oestrogen regulation of FGF1 in normal and cancer breast cells. Biochimica et biophysica acta 16 9630568
2023 FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15 36934380
2022 LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis. British journal of cancer 15 35864158
2021 RAGE: A potential therapeutic target during FGF1 treatment of diabetes-mediated liver injury. Journal of cellular and molecular medicine 15 33788387
2001 Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas. Journal of clinical pathology 15 11271786
2022 Genetically engineered FGF1-sericin hydrogel material treats intrauterine adhesion and restores fertility in rat. Regenerative biomaterials 14 35480860
2021 The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer. Frontiers in oncology 14 34552869

Missed literature

Know a paper Affinage missed for FGF1? Flag it for the maintainers and the community.

No submissions yet.